首页|期刊导航|中国实验方剂学杂志|基于"肠道菌群-肠-心轴"探讨溃疡性结肠炎与心房颤动的共病机制

基于"肠道菌群-肠-心轴"探讨溃疡性结肠炎与心房颤动的共病机制OA

Comorbidity Mechanism Between Ulcerative Colitis and Atrial Fibrillation Based on"Gut Microbiota-gut-heart"Axis

中文摘要英文摘要

肠道菌群被誉为人体的"第八大器官",在多种疾病的发生与发展过程中发挥着关键调节作用.溃疡性结肠炎(UC)是一种病因复杂、易反复发作的慢性炎性肠病,近年来研究表明,肠道菌群紊乱在其病理过程中具有关键影响.同时,越来越多的研究发现,肠道菌群失衡及其代谢产物异常也与心房颤动(AF)的发生密切相关.虽然UC与AF分别归属于消化系统与心血管系统疾病,但两者均表现出系统性炎症特征,且常伴随肠道菌群失调及代谢产物异常.然而,关于肠道菌群代谢产物在这两种疾病中作用机制的系统性研究仍较为缺乏.基于此,该研究采用文献整理及理论分析方法,以"肠道菌群-肠-心"轴为切入点,系统梳理短链脂肪酸(SCFAs)、胆汁酸(BAs)与氧化三甲胺(TMAO)3类关键代谢物在UC-AF共病机制的信号网络.研究发现,上述代谢物可能通过激活核转录因子-κB(NF-κB)、NOD样受体热蛋白结构域相关蛋白3(NLRP3)等关键炎症通路,协同介导肠道屏障功能障碍和系统炎症,构建潜在的共病网络.在此基础上,进一步探讨了益生菌干预和粪菌移植等潜在干预UC-AF共病治疗的策略.该研究旨在为跨系统疾病的防治策略提供新的理论依据与研究思路.

The gut microbiota is regarded as the"eighth organ"of the human body and plays a critical regulatory role in the occurrence and progression of various diseases.Ulcerative colitis(UC)is a chronic inflammatory bowel disease with a complex etiology and a tendency toward recurrent episodes.In recent years,studies have shown that gut microbiota dysbiosis plays a key role in its pathological processes.Meanwhile,an increasing number of studies have demonstrated that imbalances in the gut microbiota and abnormalities in its metabolites are closely associated with the development of atrial fibrillation(AF).Although UC and AF belong to diseases of the digestive system and cardiovascular system,respectively,both exhibit systemic inflammatory characteristics and are often accompanied by gut microbiota dysregulation and abnormal metabolic products.However,systematic investigations into the mechanisms by which gut microbiota-derived metabolites act in these two diseases remain limited.Based on this,the present study adopts literature review and theoretical analysis methods,taking the"gut microbiota-gut-heart"axis as the entry point,to systematically summarize the signaling networks of three key classes of metabolites,i.e.,short-chain fatty acids(SCFAs),bile acids(BAs),and trimethylamine N-oxide(TMAO),in the comorbidity mechanism of UC and AF.The findings indicate that these metabolites may activate key inflammatory pathways,such as NF-κB and NLRP3,thereby synergistically mediating intestinal barrier dysfunction and systemic inflammation and constructing a potential comorbidity network.On this basis,potential intervention strategies for the treatment of UC-AF comorbidity,including probiotic intervention and fecal microbiota transplantation,are further discussed.This study aims to provide new theoretical evidence and research perspectives for prevention and treatment strategies of cross-system diseases.

冯美玉;张雯静;杜宜航;丁炫烨;胡元会;苑海涛

山东第一医科大学,济南 250117||中国中医科学院广安门医院,北京 100053中国中医科学院广安门医院,北京 100053||中国中医科学院研究生院,北京 100700中国中医科学院广安门医院,北京 100053||中国中医科学院研究生院,北京 100700山东第一医科大学,济南 250117||中国中医科学院广安门医院,北京 100053中国中医科学院广安门医院,北京 100053山东省立医院,济南 250021

医药卫生

肠道菌群肠道菌群代谢物心房颤动溃疡性结肠炎粪菌移植

gut microbiotagut microbiota metabolitesatrial fibrillationulcerative colitisfecal microbiota transplantation

《中国实验方剂学杂志》 2026 (7)

276-281,6

国家自然科学基金项目(82074409)首都卫生发展科研专项(首发2022-1-4153)中国中医科学院科技创新工程-重大攻关项目(CI2021A00918)

10.13422/j.cnki.syfjx.20251440

评论